The lawsuit claims that three major healthcare companies were pushing up the price of insulin by 1,200 percent.

CVS Caremark Rx blasted the findings for cherry picking certain drugs in an effort to push what it called an 'anti-PBM' ...

The FTC report found that from 2017 to 2022, three PBMs—UnitedHealth Group's Optum, CVS Health's CVS Caremark and Cigna's ...

Between 2017 and 2022, UnitedHealth Group’s Optum, Cigna’s Express Scripts and CVS Health’s CVS Caremark marked up their ...

The Federal Trade Commission voted unanimously to release additional findings from its yearslong probe into CVS Caremark, ...

The Federal Trade Commision (FTC) found prescription benefits managers like UnitedHealth's OptumRX have gained $7.3B from ...

Witty's comments came during the company's first earnings call since the killing of Brian Thompson, the CEO of the company's insurance arm UnitedHealthcare.

From 2017 to 2022, the companies marked up prices at their pharmacies by hundreds or thousands of percent, netting them $7.3 billion in revenue.

According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...

We recently published a list of 10 Companies Reflect Market Decline. In this article, we are going to take a look at where ...

But high medical costs contributed to results that disappointed Wall Street, and the company’s stock fell on the news that it ...

CVS’ efforts to reform how its pharmacies are paid have reached a significant milestone that should stabilize flagging ...